{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:58:29Z","timestamp":1791406709372,"version":"4.3.3"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bacterial bloodstream infections (BSIs) cause morbidity and mortality in children with chemotherapy-associated neutropenia. While levofloxacin prophylaxis reduces BSI incidence, breakthrough infections occur in ~20%, often with fluoroquinolone non-susceptible (FQN-NS) gram-negative (GN) pathogens. The impact of FQN-NS on outcomes of GN BSI remains unknown. This study compares outcomes in pediatric patients with hematologic malignancies following FQN-NS vs. fluoroquinolone-susceptible (FQN-S) GN BSI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center cohort of pediatric patients with hematologic malignancies and neutropenia-associated GN BSI between 2014 and 2023 was retrospectively collected. The exposure was dichotomized as FQN-NS vs. FQN-S. Primary outcomes were intensive care unit admission and 30-day all-cause mortality, assessed from the day before to 30 days after blood culture collection. Modified Poisson regression with inverse probability of treatment weighting (IPTW) was used to balance covariates including age, calendar year of diagnosis, time from malignancy onset, cumulative neutropenia, granulocyte colony-stimulating factor use, international status, relapse\/refractory disease, and type of underlying hematologic malignancy. A subgroup analysis assessed effect modification by resistance to empiric therapy. Only 5 patients contributed multiple events; clustering adjustments were not made.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 119 GN BSI events, 82 (68.9%) were FQN-S and 37 (31.1%) FQN-NS. In IPTW-adjusted analyses, FQN-NS BSI was associated with higher 30-day all-cause mortality (aRR: 2.62, 95% CI: 0.39-17.64) and sepsis-related mortality (aRR: 2.60, 95% CI: 0.16-41.65), although confidence intervals were wide and not statistically significant. In a subgroup restricted to patients who received effective empiric therapy, estimates further reverted toward the null.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Fluoroquinolone non-susceptible GN BSI during neutropenia after chemotherapy was associated with increased 30-day all-cause and sepsis-related mortality in pediatric patients with hematologic malignancies, although not statistically significant. Effect modification by empiric therapy may have contributed to this association, suggesting that FQN-NS itself may not directly drive poor outcomes, but its impact appears mediated through resistance to empiric therapy, which is associated with worse outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpids\/piaf091","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T11:09:44Z","timestamp":1759576184000},"source":"Crossref","is-referenced-by-count":1,"title":["Fluoroquinolone Susceptibility and Comparative Outcomes of Gram-negative Bloodstream Infection in Pediatric Patients With Hematologic Malignancy"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0439-4898","authenticated-orcid":false,"given":"Eleana","family":"Vasileiadi","sequence":"first","affiliation":[{"name":"Division of Infectious Disease, Department of Pediatrics, Children\u2019s Hospital of Philadelphia , Philadelphia, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin W","family":"Elgarten","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia , Philadelphia, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly D","family":"Getz","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania , Philadelphia, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Aplenc","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia , Philadelphia, PA ,","place":["United States"]},{"name":"Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania , Philadelphia, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8224-4281","authenticated-orcid":false,"given":"Brian T","family":"Fisher","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Pediatrics, Children\u2019s Hospital of Philadelphia , Philadelphia, PA ,","place":["United States"]},{"name":"Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania , Philadelphia, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"key":"2025102908155266500_ref1","doi-asserted-by":"publisher","first-page":"1063253","DOI":"10.3389\/fonc.2022.1063253","article-title":"Mortality in pediatric oncology and stem cell transplant patients with bloodstream infections","volume":"12","author":"Willis","year":"2023","journal-title":"Front Oncol"},{"key":"2025102908155266500_ref2","doi-asserted-by":"publisher","first-page":"e0246654","DOI":"10.1371\/journal.pone.0246654","article-title":"Pediatric fever in neutropenia with bacteremia-pathogen distribution and in vitro antibiotic susceptibility patterns over time in a retrospective single-center cohort study","volume":"16","author":"Stergiotis","year":"2021","journal-title":"PLoS One"},{"key":"2025102908155266500_ref3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jmii.2015.08.013","article-title":"Bloodstream infections in pediatric patients with acute leukemia: emphasis on gram-negative bacteria infections","volume":"50","author":"Kuo","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"2025102908155266500_ref4","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1001\/jama.2018.12512","article-title":"Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial","volume":"320","author":"Alexander","year":"2018","journal-title":"JAMA"},{"key":"2025102908155266500_ref5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/cid\/ciz1082","article-title":"Guideline for antibacterial prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation","volume":"71","author":"Lehrnbecher","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025102908155266500_ref6","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/cncr.24812","article-title":"Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms","volume":"116","author":"Rangaraj","year":"2010","journal-title":"Cancer"},{"key":"2025102908155266500_ref7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jinf.2018.05.004","article-title":"Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: data from a surveillance program in 8755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014","volume":"77","author":"Kern","year":"2018","journal-title":"J Inf Secur"},{"key":"2025102908155266500_ref8","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1200\/JCO.22.02224","article-title":"Guideline for the Management of Fever and Neutropenia in Pediatric patients with cancer and hematopoietic cell transplantation recipients: 2023 update","volume":"41","author":"Lehrnbecher","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025102908155266500_ref9","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.3389\/fmicb.2016.01591","article-title":"Fitness cost of fluoroquinolone resistance in clinical isolates of Pseudomonas aeruginosa differs by type III secretion genotype","volume":"7","author":"Agnello","year":"2016","journal-title":"Front Microbiol"},{"key":"2025102908155266500_ref10","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1086\/522533","article-title":"A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation","volume":"45","author":"Castagnola","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2025102908155266500_ref11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/10428194.2018.1466293","article-title":"Infectious complications in children treated for Hodgkin and non-Hodgkin lymphomas in polish pediatric leukemia\/lymphoma study group: incidence, epidemiology and etiology","volume":"60","author":"Zajac-Spychala","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2025102908155266500_ref12","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"Clinical and Laboratory Standards Institute","year":"2023","edition":"33rd"},{"key":"2025102908155266500_ref13","volume-title":"Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters","author":"Clinical and Laboratory Standards Institute","year":"2019","edition":"2nd"},{"key":"2025102908155266500_ref14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/PCC.0000000000001222","article-title":"The epidemiology of hospital death following Pediatric severe sepsis: when, why, and how children with sepsis die","volume":"18","author":"Weiss","year":"2017","journal-title":"Pediatr Crit Care Med"},{"key":"2025102908155266500_ref15","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/jac\/dkz457","article-title":"Aminoglycoside versus carbapenem or piperacillin\/tazobactam treatment for bloodstream infections of urinary source caused by gram-negative ESBL-producing Enterobacteriaceae","volume":"75","author":"Zohar","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025102908155266500_ref16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/jac\/dkn469","article-title":"Aminoglycoside drugs in clinical practice: an evidence-based approach","volume":"63","author":"Leibovici","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2025102908155266500_ref17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.diagmicrobio.2018.10.019","article-title":"Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia","volume":"93","author":"Phe","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025102908155266500_ref18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/jpids\/piad041","article-title":"Emerging resistance trends in Viridans group streptococci bloodstream infections among immunocompromised children receiving levofloxacin prophylaxis","volume":"12","author":"Quintero","year":"2023","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025102908155266500_ref19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/jhm.877","article-title":"The clinical impact of fluoroquinolone resistance in patients with E coli bacteremia","volume":"6","author":"Camins","year":"2011","journal-title":"J Hosp Med"},{"key":"2025102908155266500_ref20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1086\/432940","article-title":"Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy","volume":"41","author":"Lautenbach","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2025102908155266500_ref21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/jac\/dki026","article-title":"Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes","volume":"55","author":"Hsu","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2025102908155266500_ref22","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10030266","article-title":"Antibiotic resistant bloodstream infections in Pediatric patients receiving chemotherapy or hematopoietic stem cell transplant: factors associated with development of resistance, intensive care admission and mortality","volume":"10","author":"Castagnola","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2025102908155266500_ref23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.mayocp.2011.12.003","article-title":"Mechanisms of resistance and clinical relevance of resistance to \u03b2-lactams, glycopeptides, and fluoroquinolones","volume":"87","author":"Rice","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"2025102908155266500_ref24","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s41429-024-00761-z","article-title":"Investigation of plasmid-mediated quinolone resistance among extended-spectrum \u03b2-lactamase isolates of E. coli and K. pneumoniae","volume":"77","author":"Kadry","year":"2024","journal-title":"J Antibiot (Tokyo)"},{"key":"2025102908155266500_ref25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1469-0691.2004.00723.x","article-title":"Relationship between ciprofloxacin resistance and extended-spectrum beta-lactamase production in Escherichia coli and Klebsiella pneumoniae strains","volume":"10","author":"Tolun","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"2025102908155266500_ref26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1089\/mdr.2014.0053","article-title":"Prevalence and characterization of plasmid-mediated quinolone resistance genes in extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in a Tunisian hospital","volume":"21","author":"Ferjani","year":"2015","journal-title":"Microb Drug Resist"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piaf091\/64493955\/piaf091.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/14\/10\/piaf091\/64493955\/piaf091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/14\/10\/piaf091\/64493955\/piaf091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:16:00Z","timestamp":1761740160000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/doi\/10.1093\/jpids\/piaf091\/8273789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piaf091","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10]]},"article-number":"piaf091"}}